EGFR activation in head and neck squamous cell carcinoma (HNSCC) through overexpression and autocrine/paracrine mechanisms is frequent and antibody-based EGFR inhibitors such as cetuximab are approved therapeutics that provide benefit [13–16]. Here, EGFR is linked to head and neck squamous cell carcinoma.